Renaissance Capital logo

Theseus Pharmaceuticals Priced, Nasdaq: THRX

Preclinical biotech developing pan-variant kinase inhibitors for solid tumors.

Industry: Health Care

Latest Trade: $4.06 0.00 (0.0%)

First Day Return: +16.1%

Return from IPO: -74.6%

Industry: Health Care

We are a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Our initial focus is on developing the next generation of tyrosine kinase inhibitors, or TKIs, and is rooted in the critical role that tyrosine kinases play in the development of cancer. Our goal is to develop “pan-variant” kinase inhibitors -- inhibitors that target all major cancer causing and drug resistance mutations in clinically significant protein kinases. Our lead product candidate, THE-630, is a pan-variant inhibitor of all major classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors, or GIST, a type of cancer characterized by oncogenic activation of KIT. THE-630 is derived from intellectual property exclusively licensed to us by ARIAD Pharmaceuticals, Inc., or ARIAD. We plan to submit an Investigational New Drug, or IND, application to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2021 for the evaluation of THE-630 in patients with advanced GIST whose disease has developed resistance to prior KIT-targeting therapies, and, if accepted, initiate a phase 1/2 dose escalation and expansion clinical trial.
more less
IPO Data
IPO File Date 09/15/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $160
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/06/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.0
Deal Size ($mm) $160
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
Leerink Partners
more
Company Data
Headquarters Cambridge, MA, United States
Founded 2017
Employees at IPO 14
Website theseusrx.com

Theseus Pharmaceuticals (THRX) Performance